Bipolar disorder treatment for Lantana — the diagnosis primary care misses.

RECO Integrated Psychiatry sits eighteen minutes south of Lantana on Federal Highway — the closest specialist-level outpatient psychiatry office for residents of Hypoluxo Island, Manalapan, and Ocean Ridge. The bipolar protocol runs lithium monitoring, lamotrigine titration, valproate levels, and second-generation antipsychotic selection at a level of care most primary care offices and general psychiatry practices don't offer. Diagnosis comes first: MDQ, HCL-32, structured hypomania history, and mood charting before any medication decision. In-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS.

Lantana and Hypoluxo Island sit on the barrier stretch between Delray Beach and West Palm Beach, roughly eighteen minutes south of RECO Integrated Psychiatry via Federal Highway — less if A1A is running clean through Manalapan and Gulf Stream. For residents of Old Town Lantana, Ocean Ridge, and the small island communities off the ICW, the practice is the closest outpatient psychiatry office running a full bipolar disorder protocol: structured diagnostic evaluation, lithium and lamotrigine management, second-generation antipsychotic selection, and coordination with psychotherapy modalities that have actual evidence in bipolar illness.

Bipolar I versus bipolar II versus bipolar spectrum

The DSM-5-TR distinction between bipolar I, bipolar II, and the bipolar spectrum is not academic — it drives every medication decision that follows. Bipolar I requires at least one manic episode: seven days of elevated or irritable mood with functional impairment or hospitalization. Bipolar II requires a hypomanic episode of four days or more plus a discrete major depressive episode, without ever having crossed into full mania. Bipolar spectrum captures BP-NOS, cyclothymia, subthreshold presentations, and antidepressant-induced hypomania — patients with clear cyclicity whose history does not fit clean criteria.

The pharmacology follows the phenotype. Bipolar I responds to mood stabilizers paired with second-generation antipsychotics during acute mania and for maintenance. Bipolar II depression — the pole patients spend most of their illness in — has the strongest evidence for lamotrigine and quetiapine, with a weaker case for lithium in isolation. Bipolar spectrum requires the most judgment: antidepressants can precipitate mood switches, so mood stabilizer cover comes first, and any SSRI or SNRI trial is monitored with structured mood charting.

Our bipolar disorder treatment evaluation uses the Mood Disorder Questionnaire (MDQ), HCL-32, and a structured hypomania history that most fifteen-minute medication visits skip. Misdiagnosis of bipolar depression as unipolar major depressive disorder drives the majority of treatment failures in this population — patients cycle through five or six SSRIs before anyone asks the right questions about elevated episodes, sleep-independence, and family history.

Lithium: the treatment we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with reproducible anti-suicide evidence. Response rates in classical bipolar I hover around 60-70% for maintenance, and lithium responders often achieve sustained euthymia on monotherapy — an outcome combination regimens rarely match.

The clinical inconvenience explains why many outpatient clinicians avoid it. Baseline labs include TSH, creatinine, calcium, CBC, and pregnancy testing where relevant. Maintenance targets sit between 0.6 and 1.0 mEq/L, with levels drawn twelve hours post-dose. During titration, levels are checked every one to two weeks; once stable, quarterly through the first year and every six months thereafter. Thyroid function and renal function are re-checked at six-month intervals.

Weight gain, tremor, polyuria, and long-term thyroid or renal effects require honest counseling before initiation. RECO’s protocol builds the monitoring into the treatment plan rather than treating it as an afterthought — patients who tolerate lithium usually stay on it, and the outcomes justify the labs.

Second-generation antipsychotics and where they fit

Quetiapine, lurasidone, aripiprazole, olanzapine, olanzapine-fluoxetine combination, cariprazine, and risperidone all carry FDA approval for specific bipolar indications, and choosing among them is a phase-specific decision. Quetiapine covers bipolar depression, acute mania, and maintenance — the broadest label in the class — but sedation and metabolic burden are real. Lurasidone and cariprazine are cleaner metabolically and both perform in bipolar depression, though lurasidone requires 350 calories of food to reach therapeutic absorption.

Aripiprazole and risperidone earn their place in mania and maintenance where sedation is not tolerable, though akathisia becomes the trade-off and needs to be screened for at every visit. Olanzapine and the olanzapine-fluoxetine combination remain among the most effective options for treatment-resistant bipolar depression, at the cost of the heaviest metabolic profile in the class.

Metabolic monitoring is standard: weight and BMI at every visit, HbA1c and fasting lipids at baseline and annually, blood pressure at each visit. Prior response history — patient and first-degree relatives — carries more weight than any published algorithm when the choice comes down to two options with similar evidence.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence for bipolar II depression and for maintenance in patients whose predominant pole is depressive. The titration is deliberately slow — 25 mg daily for two weeks, 50 mg daily for two weeks, 100 mg daily for one week, then 200 mg — because rapid escalation raises the risk of Stevens-Johnson syndrome. Any rash in the first two months warrants immediate evaluation. Lamotrigine is not effective for acute mania and should not be used as monotherapy in bipolar I with prominent manic features.

Valproate (divalproex) is a first-line option for acute mania and mixed states, with a therapeutic target of 50-125 mcg/mL and monitoring of LFTs, platelets, and CBC. Weight gain, hair thinning, and hepatotoxicity are known trade-offs; valproate is generally avoided in women of childbearing potential without secure contraception given teratogenicity, including neural tube defects and reduced IQ in exposed offspring.

Carbamazepine and oxcarbazepine are second-line anticonvulsants for mania, with carbamazepine requiring HLA-B*1502 screening in patients of Asian ancestry and cytochrome P450 induction that complicates polypharmacy. Each protocol has a defined monitoring schedule, and RECO’s outpatient practice runs all of them rather than referring out.

What to expect on your first visit

The initial evaluation is 75 to 90 minutes with a psychiatrist and covers a full psychiatric history, mood chronology, family history of bipolar disorder and suicide, prior medication trials with detailed response and side effect notes, substance use screening, and structured assessment with the MDQ, HCL-32, PHQ-9, and GAD-7. Where prior treatment has failed, the ASRS is used to screen for adult ADHD, which co-occurs with bipolar II at rates above 20% and complicates any stimulant decision.

No medication decision is made in the first visit unless the presentation is acute. Baseline labs — CBC, CMP, TSH, HbA1c, fasting lipids, pregnancy testing where relevant, and a urine drug screen — are ordered before initiation of lithium, valproate, or a second-generation antipsychotic. Follow-up visits during titration run every one to two weeks; once stable, monthly, then every three months for maintenance.

Insurance and admissions from Lantana

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Coverage for outpatient psychiatric evaluation, medication management, and standard lab monitoring is straightforward across these plans; TMS and Spravato (esketamine) coverage requires prior authorization documenting failed antidepressant trials, and the admissions team submits that paperwork directly to the payer.

From Lantana the drive is eighteen minutes via Federal Highway, or slightly shorter along A1A through Manalapan when I-95 is heavy. Same-week evaluations are usually available. Telepsychiatry follow-ups are offered for established patients whose schedules make in-person visits difficult, though initial evaluations and any Spravato or TMS treatment are conducted on-site.

Serving residents of: Hypoluxo Island, Manalapan, Ocean Ridge, Old Town Lantana.